Determination of levamisole, aminorex, and pemoline in plasma by means of liquid chromatography-mass spectrometry and application to a pharmacokinetic study of levamisole

Drug Testing and Analysis

Volumn 6, Issue 10, 2014, Pages 1049-1054

  Hess, Cornelius ^a   Ritke, Natalie ^a   Sydow, Konrad ^a   Mehling, Lena Maria ^a   Ruehs, Hauke ^a   Madea, Burkhard ^a   Musshoff, Frank ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Forensic Toxicological Center FTC   (Germany)

Author keywords

Aminorex; Cocaine adulterants; LC MS MS; Levamisole; Pemoline; Pharmacokinetics

Indexed keywords

BODY FLUIDS; CALIBRATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES;

AMINOREX; CALIBRATION CURVES; COCAINE ADULTERANT; HUMAN PLASMAS; LEVAMISOLE; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY/MS; PEMOLINE; PHARMACOKINETIC STUDIES;

PHARMACOKINETICS;

AMINOREX; COCAINE; LEVAMISOLE; MEBENDAZOLE; PEMOLINE; ANTHELMINTIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; KIDNEY CONCENTRATING CAPACITY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; BIOLOGICAL MODEL; HALF LIFE TIME; METABOLISM; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ADULT; AMINOREX; ANTHELMINTICS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; HALF-LIFE; HUMANS; LEVAMISOLE; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MODELS, BIOLOGICAL; PEMOLINE;

EID: 84916882721     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1619     Document Type: Article

References (19)

1. S. Schneider, F. Meys. Analysis of illicit cocaine and heroin samples seized in Luxembourg from 2005-2010. Forensic Sci. Int. 2011, 212, 242.
2. N.Y. Zhu, D.F. Legatt, A.R. Turner. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann. Intern. Med. 2009, 150, 287.
3. A. Wolford, T.S. McDonald, H. Eng. Immune-mediated agranulocytosis caused by the cocaine adulterant levamisole: A case for reactive metabolite(s) involvement. Drug Metab. Dispos. 2012, 40, 1067.
4. J.A. Buchanan, E.J. Lavonas. Agranulocytosis and other consequences due to use of illicit cocaine contaminated with levamisole. Curr. Opin. Hematol. 2012, 19, 27.
5. N.M. Walsh, P.J. Green, R.W. Burlingame, S. Pasternak, J.G. Hanly. Cocaine-related retiform purpura: Evidence to incriminate the adulterant, levamisole. J. Cutan. Pathol. 2010, 37, 1212.
6. E.K. Farhat, T.T. Muirhead, M.L. Chaffins, M.C. Douglass. Levamisole-induced cutaneous necrosis mimicking coagulopathy. Arch. Dermatol. 2010, 146, 1320.
7. E. Bertol, F. Mari, M.G. Milia, L. Politi, S. Furlanetto, S.B. Karch. Determination of aminorex in human urine samples by GC-MS after use of levamisole. J. Pharm. Biomed. Anal. 2011, 55, 1186.
8. C. Hess, N. Ritke, S. Broecker, B. Madea, F. Musshoff. Metabolism of levamisole and kinetics of levamisole and aminorex in urine by means of LC-QTOF-HRMS and LC-QqQ-MS. Anal. Bioanal. Chem. 2013, 405, 4077.
9. E.N. Ho, D.K. Leung, G.N. Leung. Aminorex and rexamino as metabolites of levamisole in the horse. Anal. Chim. Acta 2009, 638, 58.
10. J. Gutierrez, R.L. Eisenberg, N.J. Koval, E.R. Armstrong, J. Tharappel, C.G. Hughes, T. Tobin. Pemoline and tetramisole 'positives' in English racehorses following levamisole administration. Irish Vet J. 2010, 63, 498.
11. F.T. Peters, O.H. Drummer, F. Musshoff. Validation of new methods. Forensic Sci. Int. 2007, 165, 216.
12. F.T. Peters, M. Hartung, M. Herbold, G. Schmitt, T. Daldrup, F. Mußhoff. Anhang B zur Richtlinie der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen: Anforderung an die Validierung von Analysensystemen, 2011. Available at: http://www.gtfch.org/cms/index.php/en/guidelines [14 February 2014].
13. B.K. Matuszewski, M.L. Constanzer, C.M. Chavez-Eng. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: A method for determination of finasteride in human plasma at picogram per milliliter concentrations. Anal. Chem. 1998, 70, 882.
14. S.L. Beal, L.B. Sheiner. NONMEM User's Guide. NONMEM Project Group, University of California, San Francisco, CA, 1998.
15. F.T. Peters, O.H. Drummer, F. Musshoff. Validation of new methods. Forensic Sci. Int. 2007, 165, 216.
16. J.M.W. Heykants. Levamisole pharmacokinetics in healthy volunteers and in cancer patients. A review of the data available until January 1990, unpublished report no. R12564/117. Janssen Research Foundation, Janssen Pharmaceutica, Beerse, Belgium, 1990.
17. E. Kouassi, G. Caille, L. Lery, L. Lariviere, M. Vezina. Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm. Drug Dispos. 1986, 7, 71.
18. L. Tong, L. Ding, Y. Li, Z. Wang, J. Wang, Y. Liu, L. Yang, A. Wen. A sensitive LC-MS/MS method for determination of levamisole in human plasma: application to pharmacokinetic study. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2011, 879, 299.
19. A. Van Peer. Phase-I trial: Systemic absorption of levamisole after single oral doses of 1, 10 and 50 mg to healthy volunteers, unpublished report trial no. LVM-GBR-2. Janssen Research Foundation, Janssen Pharmaceutica, Beerse, Belgium. 1993.